Global Benign Mesonephroma Market, By Diagnosis (Ultrasound, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Others), Treatment (Surgery, Chemotherapy, Radiation Therapy, Tyrosine Kinase Inhibitors, Others), Sites (Broad Ligament, Mesosalpinx, Ovaries, Fallopian Tubes, Paravaginal, Peritoneum), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Benign Mesonephroma Market Analysis and Size
Benign mesonephroma is an uncommon type of tumor that is witnessed anywhere between the ovary and the vaginal canal in leftover wolffian ducts. The recommended treatment for these patients is surgery. Recurrences or malignancy have been witnessed in a limited proportion of cases. The increasing number of cases of benign mesonephroma is a primary factor pushing the market's growth rate during the forecast period.
Data Bridge Market Research analyses a growth rate in the benign mesonephroma market in the forecast period 2023-2030. The expected CAGR of the benign mesonephroma market tends to be around 6.7% in the mentioned forecast period. The market value is USD 311.5 million in 2022, and it would grow up to USD 523.4 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Benign Mesonephroma Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Ultrasound, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Others), Treatment (Surgery, Chemotherapy, Radiation Therapy, Tyrosine Kinase Inhibitors, Others), Sites (Broad Ligament, Mesosalpinx, Ovaries, Fallopian Tubes, Paravaginal, Peritoneum), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Lilly (U.S.), AbbVie Inc. (U.S.), Lupin (India)
|
|
Market Opportunities
|
|
Market Definition
Benign mesonephroma are the type of uncommon neoplasms which arise from remains of the Wolffian duct. These tumors frequently begin in the wide ligament and para-ovarian area. In treating recurring benign mesonephroma, chemotherapy and radiation therapy are a bit doubtful. In certain individuals with c-Kit+ malignancies, tyrosine kinase inhibitors which includes imatinib were also utilized. This condition is then termed as female adnexal tumors of probable Wolffian origin (FATWOs).
Benign Mesonephroma Market Dynamics
Drivers
- Increased Incidence of Benign Mesonephroma
The increasing number of cases of benign mesonephroma is a primary factor boosting the market's growth rate during the forecast period. Benign mesonephroma are rare tumors that start from the remains of the mesonephric duct and can later become cancerous. The use of tyrosine kinase inhibitors for treating c-kit positive cancers has shown some potential, but further research is required. The disease generally occurs in children younger than 2 years, and survival rates witnessed is poor, with less than 25% of patients alive at 2 years. Thus, it boosts market growth.
- Increased Healthcare Expenditure
A major factor influencing the benign mesonephroma market is the increasing healthcare expenditure that helps improve its infrastructure. Furthermore, numerous government organizations aim to improve the healthcare infrastructure by increasing funding, further boosting market dynamics.
Opportunities
- Growing R&D Activities
The market growth rate is boosted by an increase in the number of R&D activities. This will provide much better opportunities for the benign mesonephroma market growth. The European Organization for Rare Diseases (EURORDIS) estimates that around 6% to 8% of the population in the European Union is majorly affected by a rare disorder. Thus, numerous research laboratories are primarily focusing on R&D to meet the demand for certain therapies for the treatment of uncommon conditions such as rare cardiovascular diseases and deadly familial insomnia. As the awareness is growing, the market will continue to flourish.
Restraints/Challenges
- High Cost of Treatment Methods
The huge expenditure that is related with these agents restricts the market growth. Treatments that include thoracotomy, laparotomy and laparoscopy, heat therapy impede the growth of the market.
This benign mesonephroma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the benign mesonephroma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Global Benign Mesonephroma Market Scope
The benign mesonephroma market is segmented on the basis of diagnosis, treatment, sites, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Sites
- Broad Ligament
- Mesosalpinx
- Ovaries
- Fallopian Tubes
- Paravaginal
- Peritoneum
Diagnosis
- Ultrasound
- Computed Tomography (CT) Scan
- Magnetic Resonance Imaging (MRI)
- Others
Treatment
- Surgery
- Chemotherapy
- Paclitaxel
- Carboplatin
- Others
- Radiation Therapy
- Tyrosine Kinase Inhibitors
- Imatinib
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Benign Mesonephroma Market Regional Analysis/Insights
The benign mesonephroma market is analyzed and market size insights and trends are provided by diagnosis, treatment, sites, end-user and distribution channel as referenced above.
The major countries covered in the benign mesonephroma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Europe has been witnessing the highest growth for the benign mesonephroma market throughout the forecasted period because of the development of healthcare infrastructure in this region. Furthermore, increasing government initiatives will further boost the market’s growth rate in this region.
North America dominates the market because of the increasing occurrence of benign mesonephroma and growing healthcare expenditure, this will further boost the market’s growth rate. Furthermore, the increasing presence of major key players will further push the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Benign Mesonephroma Market Share Analysis
The benign mesonephroma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to benign mesonephroma market.
Key players operating in the benign mesonephroma market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Lilly (U.S.)
- AbbVie Inc. (U.S.)
- Lupin (India)
SKU-